---
layout: startup_page
title: "Asceneuron SA"
id: "asceneuron.com"
permalink: "/asceneuronsaasceneuron.com03312025/"
website: "https://www.asceneuron.com/"
funding_round: "Series C"
funding_amount: "$100M"
investors: "Novo Holdings, OrbiMed, SR One, M Ventures, Sofinnova Partners, GSK Equities Investments Limited, Johnson & Johnson Innovation, EQT Life Sciences, LSP Dementia Fund"
about: "Asceneuron is a clinical-stage biotech company developing small molecule drugs targeting tau protein aggregation, a root cause of neurodegenerative diseases. Their lead asset, ASN51, is an oral drug designed to inhibit OGA, an enzyme implicated in protein aggregation, aiming to slow the progression of Alzheimer's and other neurodegenerative diseases. Asceneuron has completed five early-stage clinical trials demonstrating the drug's effectiveness in reaching the brain and targeting the OGA enzyme."
markets: "Biotechnology, Pharmaceuticals, Neurodegenerative Diseases, Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease"
hq: "Lausanne, Vaud, Switzerland"
founded_year: "2012"
linkedin: "https://www.linkedin.com/company/asceneuron-sa"
twitter: "https://x.com/asceneuron_sa"
instagram: ""
facebook: ""
crunchbase: "https://www.crunchbase.com/organization/asceneuron"
pitchbook: ""

# SEO Optimization
meta_title: "Asceneuron SA - Series C Funding ($100M)"
meta_description: "Asceneuron SA, Asceneuron is a clinical-stage biotech company developing small molecule drugs targeting tau protein aggregation, a root cause of neurodegenerative di..."
meta_keywords: "Asceneuron SA, Biotechnology, Pharmaceuticals, Neurodegenerative Diseases, Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Series C funding"
canonical_url: "https://pkprojectstartups.github.io/projectstartups.com/asceneuronsaasceneuron.com03312025/"
---